- Home
- KNOP vs ZNTL Comparison
KNOP vs ZNTL Comparison
Compare KNOP & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | ZNTL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.2M | 289.0M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KNOP | ZNTL |
|---|---|---|
| Price | $9.95 | $2.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $14.50 | $7.44 |
| AVG Volume (30 Days) | 41.3K | ★ 1.4M |
| Earning Date | 12-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.65 | N/A |
| Revenue Next Year | $0.75 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.77 | $1.21 |
| 52 Week High | $11.78 | $6.95 |
Technical Indicators
Market Signals| Indicator | KNOP | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 32.39 |
| Support Level | $9.88 | N/A |
| Resistance Level | $10.78 | $2.76 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 34.15 | 12.16 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.